Journal of Cardiovascular Pharmacology · 1990 · 63 citations · 0 references
MedicineNeurosciencePharmacologyNeurochemistryNeuropharmacologyPharmacodynamicsCholinergic NeurochemistryCholinergic PharmacologyCholinergic SignalingNeurochemical PharmacologyReceptor PharmacologyAcetylcholine PharmacologyAcetylcholine Receptor PharmacologyCentral Cholinergic PharmacologyCholinergic Receptor PharmacologyTemporal Cortex
In the present studies we have shown that angiotensin II (AT II), in a concentration-dependent manner in rat tissue (10(-9)-10(-5) M) or at a single concentration in human tissue (10(-6) M), can inhibit potassium-stimulated release of [3H]acetylcholine ( [3H]Ach) from slices of rat entorhinal cortex and human temporal cortex preloaded with [3H]choline for the biochemical analyses. The inhibitory effects of AT II (10(-6) M) were antagonised by the specific AT II receptor antagonist [1-sarcosine, 8-threonine]AT II in a concentration-dependent manner in rat tissue (10(-11)-10(-8) M) and at the single concentration employed in the human studies (10(-7) M). Also demonstrated were other components of the angiotensin system in the human temporal cortex; ACE activity was present (1.03 nmol min-1 mg-1 protein), as were AT II recognition sites (Bmax = 8.6 fmol mg-1 protein). It is hypothesised that the potential cognitive enhancing properties of ACE inhibitors may reflect their action to prevent the formation of AT II and so remove an inhibitory modulator of cholinergic function.